Cemsidomide vs Thalidomide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline

Cemsidomide

Developed by C4 Therapeutics, Inc.

Phase 2 in Multiple Myelomasmall molecule (targeted protein degrader / cereblon E3 ligase modulator)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2028 · NCT07280013 (registry estimate)

No aligned efficacy figure on record for this race.

Thalidomide

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomasmall molecule (IMiD / cereblon modulator, first-generation)
Partial signal

NCT00083551 · Phase 3 · completed

The trial randomly assigned 323 participants to thalidomide and 345 to no thalidomide, but treatment was open-label rather than blinded. Its primary endpoint was the hard clinical outcome of six-year overall survival; although the reported percentages favored thalidomide, statistical significance cannot be determined from the posted registry data.

Next expected readout: August 2027 · NCT00572169 (registry estimate)

Reported efficacy

Overall Survival (6 Years): Overall Survival (6 Years): Thalidomide 65 percentage of participants | No Thalidomide 58 percentage of participants (unclear)

Result source: NCT00083551

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCemsidomideThalidomide
PFS, median—Not reported46.7bn 444NCT02541383
5 other results
OS, median—Not reported49.8bn 168NCT00507416
2 other results
ORR—Not reported73%bn 147NCT00507416
3 other results
VGPR or better—Not reported37%bn 147NCT00507416
2 other results
MRD negativity—Not reported—Not posted · NCT00083876

PFS, median

Cemsidomide
—Not reported
Thalidomide
46.7bn 444NCT02541383
5 other results

OS, median

Cemsidomide
—Not reported
Thalidomide
49.8bn 168NCT00507416
2 other results

ORR

Cemsidomide
—Not reported
Thalidomide
73%bn 147NCT00507416
3 other results

VGPR or better

Cemsidomide
—Not reported
Thalidomide
37%bn 147NCT00507416
2 other results

MRD negativity

Cemsidomide
—Not reported
Thalidomide
—Not posted · NCT00083876
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Cemsidomide: no structured comparison results are available for Multiple Myeloma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cemsidomide: 0 of 4 rows · Thalidomide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricThalidomide
Dropout rate
0%a
NCT00083551 · Phase 3 · combination
show 20 more results
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
20.7%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT00049673 · Phase 3 · registry result, not featured evidence
70.2%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
68.3%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
74.9%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
14.3%
NCT00432458 · Phase 3 · registry result, not featured evidence · combination
89.3%
NCT00097981 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT01632150 · Phase 2 · registry result, not featured evidence · combination
—
NCT00040937 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00081939 · Phase 2 · registry result, not featured evidence
0%
NCT00083382 · Phase 2 · registry result, not featured evidence · combination
11.1%
NCT00458705 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
0%1000 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
0%800 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
0%600 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT00083551 · Phase 3 · combination
show 20 more results
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
5.5%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—
NCT00049673 · Phase 3 · registry result, not featured evidence
34.5%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
38.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
40.1%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
—
NCT00432458 · Phase 3 · registry result, not featured evidence · combination
39.3%
NCT00097981 · Phase 3 · registry result, not featured evidence · combination
17.5%
NCT01632150 · Phase 2 · registry result, not featured evidence · combination
—
NCT00040937 · Phase 2 · registry result, not featured evidence · combination
—
NCT00081939 · Phase 2 · registry result, not featured evidence
—
NCT00083382 · Phase 2 · registry result, not featured evidence · combination
8.9%
NCT00458705 · Phase 2 · registry result, not featured evidence · combination
—
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
—1000 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
—800 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
—600 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
100%a
NCT00083551 · Phase 3 · combination
show 20 more results
49.3%DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
18.8%DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
27.5%VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
34.6%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
27.2%Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00049673 · Phase 3 · registry result, not featured evidence
53.3%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
50.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
58.2%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
8.6%
NCT00432458 · Phase 3 · registry result, not featured evidence · combination
50%
NCT00097981 · Phase 3 · registry result, not featured evidence · combination
—
NCT01632150 · Phase 2 · registry result, not featured evidence · combination
1.3%
NCT00040937 · Phase 2 · registry result, not featured evidence · combination
100%
NCT00081939 · Phase 2 · registry result, not featured evidence
19.3%
NCT00083382 · Phase 2 · registry result, not featured evidence · combination
48.9%
NCT00458705 · Phase 2 · registry result, not featured evidence · combination
33.3%
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
0%1000 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
0%800 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
33.3%600 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
grade 1 bicarbonate decrease 60.1% (placebo 62.9%)
grade 1 hypokalemia 54.2% (placebo 52.8%)
grade 3 anemia (hgb) 49.8% (placebo 50.4%)
NCT00083551 · Phase 3 · combination
show 19 more results
peripheral sensory neuropathy 60.6%
constipation 50.6%
asthenia 32.8%
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
bronchitis 40.6%
cough 17%
nasopharyngitis 17%
NCT02541383 · Phase 3 · registry result, not featured evidence
bronchitis 36.5%
cough 19.4%
nasopharyngitis 17.5%
NCT02541383 · Phase 3 · registry result, not featured evidence
constipation 35.8%
nausea 32.3%
peripheral sensory neuropathy 24.4%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 37.9%
peripheral sensory neuropathy 36.9%
neuropathy peripheral 29.1%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
neuropathy-sensory 89.1% (placebo 43.6%)
fatigue 72.7% (placebo 58.3%)
bone pain 72.1% (placebo 74.2%)
NCT00049673 · Phase 3 · registry result, not featured evidence
insomnia 5.5%
weight decreased 2.4%
blood sodium decreased 1.8%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
leukopenia 7.4%
platelet count decreased 4.3%
insomnia 3.7%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
hyperuricaemia 5.1%
insomnia 3.8%
cough 3.2%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
peripheral sensory neuropathy 80%
fatigue 77.1%
constipation 62.9%
NCT00432458 · Phase 3 · registry result, not featured evidence · combination
oedema peripheral 56.6%
fatigue 54.7%
constipation 45.3%
NCT00097981 · Phase 3 · registry result, not featured evidence · combination
sensory neuropathy 78.9%
fatigue/malaise/lethargy 68.4%
hyperglycemia 51.3%
NCT00040937 · Phase 2 · registry result, not featured evidence · combination
grade 1 bicarbonate decrease 72.3%
grade 2 hypoalbuminemia 68.6%
grade 1 alkaline phosphatase increase 59.7%
NCT00081939 · Phase 2 · registry result, not featured evidence
grade 1 hypomagnesemia 56.6%
grade 2 fatigue 50.6%
grade 1 hypocalcemia 47%
NCT00083382 · Phase 2 · registry result, not featured evidence · combination
thrombosis/thrombus/embolism 17.8%
constipation 11.1%
diarrhea 8.9%
NCT00458705 · Phase 2 · registry result, not featured evidence · combination
peripheral neuropathy 83.3%
fatigue 73.3%
constipation 63.3%
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
1000 mg
somnolence 100%
dysgeusia 66.7%
febrile neutropenia 66.7%
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
800 mg
diarrhea 100%
nausea 100%
somnolence 100%
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
600 mg
somnolence 100%
diarrhea 66.7%
mucositis 66.7%
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Thalidomide

PFS 46.7 months
time to event · months
No placebo or comparator arm
NCT02541383 · Phase 3 · registry result, not featured evidence
show 4 more results
52.8 months
NCT02541383 · Phase 3 · registry result, not featured evidence
14.7 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
15.4 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
17.3 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
CR or VGPR 92.9% (n=98) vs 81.3% (n=96) Thalidomide + Prednisolone @ 52wk
responder rate · % of participants
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
Complete 36.7% (n=98) vs 36.5% (n=96) Thalidomide + Prednisolone @ 13wk
responder rate · % of participants
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
show 4 more results
44.9% (n=98) vs 44.8% (n=96) Thalidomide + Prednisolone @ 26wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
52% (n=98) vs 49% (n=96) Thalidomide + Prednisolone @ 39wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
53.1% (n=98) vs 51% (n=96) Thalidomide + Prednisolone @ 52wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
7.1% (n=112) vs 4.4% (n=113) Thalidomide + Dexamethasone*
NCT00097981 · Phase 3 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted
Stringent Complete 23.5% (n=98) vs 20.8% (n=96) Thalidomide + Prednisolone @ 13wk
responder rate · % of participants
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
28.6% (n=98) vs 27.1% (n=96) Thalidomide + Prednisolone @ 26wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
30.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 39wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
28.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 52wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
PFS 22.51 vs 22.05 Thalidomide + Prednisolone months
time to event · months
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
Disease-free Survival 13.37 vs 18.53 Thalidomide + Prednisolone months
time to event · months
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
Overall Survival NA vs NA Thalidomide + Prednisolone months
time to event · months
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 30.1% (n=166) vs 36.7% (n=166) placebo @ 468wk
event count · % of participants
Death
NCT00049673 · Phase 3 · registry result, not featured evidence · converted to % from 50 Participants as posted
Progression Free Survival 60.2% (n=166) vs 76.5% (n=166) placebo @ 468wk
event count · % of participants
Disease progression
NCT00049673 · Phase 3 · registry result, not featured evidence · converted to % from 100 Participants as posted
ORR 73% (n=147)
responder rate · % of participants
No placebo or comparator arm
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
80% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
70% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
81.5% (n=27)
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
Complete 3% (n=147)
responder rate · % of participants
No placebo or comparator arm
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
4% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
4% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
VGPR or Better 37% (n=147)
responder rate · % of participants
No placebo or comparator arm
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
51% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
41% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemsidomide's landscape · Thalidomide's landscape